Rasagiline Mesylate – (161735-79-1)

Rasagiline mesylate is a potent and selective irreversible inhibitor of monoamine oxidase B (MAO-B). It is primarily used for the treatment of Parkinson’s disease, both as a monotherapy in early stages and as an adjunct therapy in more advanced cases. Rasagiline mesylate works by irreversibly binding to MAO-B, thereby increasing dopamine levels in the brain, which helps alleviate the symptoms of Parkinson’s disease.

In clinical trials, rasagiline mesylate has shown efficacy in improving motor symptoms and quality of life in Parkinson’s disease patients. However, it has not been conclusively proven to have disease-modifying effects.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Rasagiline
https://www.medchemexpress.com/rasagiline-mesylate.html
https://www.medkoo.com/products/8774
https://go.drugbank.com/salts/DBSALT001384